Derived from a novel chemistry platform and cell-based differential screening, our technology targets cancer while protecting healthy cells.

Therapeutic Focus

Onconova is focused on discovering and developing targeted, small molecule product candidates for the treatment of cancer, including Myelodysplastic Syndromes (MDS).


Onconova is a Phase 3 company with a targeted trial design and several active clinical and pre-clinical programs.

About Onconova Therapeutics

Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. The Company is actively studying rigosertib in clinical trials, and has conducted trials with two other research compounds. Onconova also has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300.

Advanced clinical trials with our lead compound, rigosertib, are aimed at medical needs of patients with myelodysplastic syndromes (MDS).  MDS is a hematological malignancy resulting in bone marrow failure which leads to acute myeloid leukemia (AML) in 30% of high-risk patients. There has been little advancement in this indication in more than a decade.  More than 10,000 patients suffer from MDS in the USA, representing a significant underserved medical need.

Onconova Therapeutics was incorporated in 1998 in Delaware and began trading on the NASDAQ stock exchange under the ticker symbol ONTX in July, 2013.

Broad pipeline includes novel drug candidates in
phase 3, early stage clinical, and pre-clinical trials

Onconova’s lead product candidate, rigosertib, a small molecule drug candidate, is currently in a pivotal phase 3 study (“INSPIRE”) for the treatment of higher-risk MDS after failure of a hypomethylating agent. Rigosertib has a unique mechanism of action that targets the Ras cancer gene product, one of the most sought after targets in oncology involved in more than 30% of human cancers.

Dr. James Holland

We were deeply saddened by the passing of Dr. James Holland,
a distinguished member of our advisory board since 2004.
Dr. Holland passed away on March 22, 2018.


Understanding Reactions
in Cancer and Normal cells

Latest Updates & News